Valuation: Sernova Biotherapeutics Inc

Market Cap 50.98M 35.88M 31.42M 29M 27.08M 3.39B 52.14M 349M 135M 1.67B 135M 132M 5.81B P/E 2026 *
-4.5x
P/E 2027 * -3.38x
Enterprise Value 50.98M 35.88M 31.42M 29M 27.08M 3.39B 52.14M 349M 135M 1.67B 135M 132M 5.81B EV / Sales 2026 *
-
EV / Sales 2027 * 10.2x
Free-Float
86.83%
Yield 2026 *
-
Yield 2027 * -
1 day-3.57%
1 week-12.90%
Current month-3.57%
1 month-3.57%
3 months-20.59%
6 months+8.00%
Current year+3.85%
1 week 0.12
Extreme 0.12
0.16
1 month 0.12
Extreme 0.12
0.17
Current year 0.12
Extreme 0.12
0.2
1 year 0.12
Extreme 0.12
0.21
3 years 0.12
Extreme 0.12
1.04
5 years 0.12
Extreme 0.12
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 60 19/04/2012
Director/Board Member - 24/04/2023
Director/Board Member - 01/09/2024
Date Insider Type Main position Quantity % Market Cap.
22/05Option

Chairman

360,000 0.1035%
22/05Option

Director

260,000 0.0748%
22/05Option

Director

260,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-12.90%-18.18%-85.16% 35.88M
-0.66%+8.48%-16.02%+9.53% 127B
-1.22%+1.25%+1.71%-10.73% 12.85B
-1.54%+8.38%+40.20%+100.80% 8.35B
+3.27%-4.20%-48.73%-71.84% 3.92B
+2.94%+3.21%+21.28%+38.60% 2.59B
+20.00%+6.96%-11.29%-10.27% 1.84B
+6.68%+7.05%+238.24%+177.06% 1.65B
+4.97%+2.12%+3.29%-23.63% 1.61B
Average +3.43%+3.18%+23.39%+13.82% 17.73B
Weighted average by Cap. -0.22%+7.62%-8.97%+12.29%

Financials

2026 *2027 *
Net sales - 5M 3.52M 3.08M 2.84M 2.66M 333M 5.11M 34.23M 13.21M 164M 13.21M 12.92M 570M
Net income -12.83M -9.03M -7.9M -7.3M -6.81M -853M -13.12M -87.81M -33.9M -421M -33.9M -33.16M -1.46B -19.77M -13.91M -12.18M -11.25M -10.5M -1.32B -20.22M -135M -52.25M -649M -52.26M -51.11M -2.25B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
29/06/26 CAD 0.1350 -3.57% 22,016
26/06/26 CAD 0.1400 0.00% 213,550
25/06/26 CAD 0.1400 0.00% 17,500
24/06/26 CAD 0.1400 -3.45% 208,654
23/06/26 CAD 0.1450 -6.45% 63,778
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1350CAD
Average target price
0.4500CAD
Spread / Average Target
+233.33%

Quarterly revenue - Rate of surprise